Merck KGaA (XSWX:MER) Other Current Receivables: CHF110 Mil (As of Mar. 2026)


XSWX:MER Merck KGaA XSWX:MER
82 GF Score
Price CHF132.80
GF Value CHF125.76
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Other Current Receivables?

Merck KGaA XSWX:MER 82 Other Current Receivables is CHF110 Mil as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 82/100 and a GF Value™ of CHF125.76. The stock has 9 warning signs investors should review.

Merck KGaA's Other Current Receivables for the quarter that ended in Mar. 2026 was CHF110 Mil.

Merck KGaA's quarterly Other Current Receivables declined from Sep. 2025 (CHF106.52 Mil) to Dec. 2025 (CHF96.11 Mil) but then increased from Dec. 2025 (CHF96.11 Mil) to Mar. 2026 (CHF110.13 Mil).

Merck KGaA's annual Other Current Receivables increased from Dec. 2023 (CHF99.02 Mil) to Dec. 2024 (CHF123.24 Mil) but then declined from Dec. 2024 (CHF123.24 Mil) to Dec. 2025 (CHF96.11 Mil).

Merck KGaA Other Current Receivables Related Terms

Merck KGaA Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Other Current Receivables Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 215.42 126.32 99.02 123.24 96.11

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.05 122.87 106.52 96.11 110.13
XSWX:MER
82GF Score
Merck KGaA XSWX:MER
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of CHF110 Mil mean?
Merck KGaA (XSWX:MER) has a Other Current Receivables of CHF110 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Other Current Receivables too high?
Merck KGaA's current Other Current Receivables is CHF110 Mil. Overall, Merck KGaA has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Other Current Receivables compare to ZTS and UTHR?
Merck KGaA's Other Current Receivables of CHF110 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Merck KGaA and its competitors. Merck KGaA's current Other Current Receivables is CHF110 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Other Current Receivables of CHF110 Mil. The stock's GF Value™ is CHF125.76, compared to a current price of CHF132.80 — trading 5.6% above its estimated fair value. The current Other Current Receivables is CHF110 Mil. Merck KGaA's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Other Current Receivables is CHF110 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of CHF132.80 is trading 5.6% above its estimated GF Value™ of CHF125.76.

Key valuation signals for XSWX:MER:

  • Other Current Receivables: CHF110 Mil
  • GF Value™: CHF125.76 vs. price of CHF132.80 (5.6% above fair value)
  • GF Score™: 82/100 with 9 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
82GF Score

Get the complete analysis for XSWX:MER

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF132.80
Price
CHF125.76
GF Value